Therapeutic vaccines for substance dependence
by
Kosten TR, Biegel D.
Yale University School of Medicine,
Department of Psychiatry,
West Haven, Connecticut 06516, USA.
thomas.kosten@yale.edu
Expert Rev Vaccines. 2002 Oct;1(3):363-71

ABSTRACT

Several immunotherapies are under development for nicotine, cocaine and phencyclidine and a cocaine vaccine has started human trials. These therapies promise a new approach to diseases that have had limited treatment success and tremendous morbidity. Both the cocaine and nicotine addiction immunotherapies have reduced 'relapse' to drug use in animal model systems. To date, the active cocaine vaccine has few side effects and induces considerable antibody titers after active immunization in humans. Studies with the monoclonal phencyclidine immunotherapy provide intriguing evidence of sustained protection for months after single-dose administration. Other immunotherapy may include treatment of drug overdose, prevention of brain or cardiac toxicity and protection of a fetus during pregnancy in a drug abuser.

CART
Metabolism
Designer drugs
Vaccine dosage
Dopaminergic flies?
Dopaminergic agents
The coke-craving brain
Vaccines against drugs
Cocaine vaccine IPC-1010
Monoamines, cocaine and rats
Cocaine and artificial enzymes
Freebasing flies go hyperkinetic
Kappa receptors, dopamine D3 and cocaine

01 02 03 04 05 06 07 08 09 10 11 12
13 14 15 16 17 18 19 20 21 22 23 24

Refs
HOME
HedWeb
cannabis-marijuana.com
Future Opioids
BLTC Research
Wirehead Hedonism
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family